Insights
Search Results
Client Highlights
10.17.25
Wilson Sonsini Advises Omeros on Asset Purchase and License Agreement with Novo Nordisk
On October 15, 2025, Novo Nordisk and Omeros Corporation announced that they have entered into a definitive asset purchase and license agreement for the candidate drug zaltenibart (OMS906) in clinical development for rare blood and kidney disorders. Wilson Sonsini Goodrich & Rosati advised Omeros on the transaction.
Client Highlights
7.21.25
Wilson Sonsini Advises Cloudflare on $2.0 Billion Convertible Senior Notes
On June 17, 2025, Cloudflare, Inc. issued $2.0 billion aggregate principal amount of 0% Convertible Senior Notes due 2030. The offering amount included the exercise in full of the option that Cloudflare had granted to the initial purchasers to purchase up to an additional $250 million of notes. In connection with the offering, Cloudflare entered into privately negotiated capped call transactions with certain of the initial purchasers or their respective affiliates and other financial institutions.
Client Highlights
12.18.23
Wilson Sonsini Advises Lithos Carbon on $57.1 Million Offtake Agreement in Largest-Ever Frontier CDR Purchase
On December 7, 2023, Frontier, an advance market commitment (AMC) that aims to accelerate the development of carbon removal technologies, announced its first enhanced weathering offtake agreements with Lithos Carbon, a San Francisco-based agricultural carbon removal company. Wilson Sonsini Goodrich & Rosati advised Lithos in the transaction.
Client Highlights
11.10.23
Wilson Sonsini Advises Alpine Immune Sciences on $150 Million Follow-on Public Offering
On November 6, 2023, Alpine Immune Sciences, Inc., a clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the pricing of its underwritten public offering of 8,800,000 shares of its common stock and pre-funded warrants to purchase up to 3,200,000 shares of its common stock, pursuant to its existing shelf registration statement. Wilson Sonsini Goodrich & Rosati advised Alpine Immune Sciences on the transaction.
Alerts
10.12.23
SPARCs: An Attractive Alternative to Traditional SPACs?
On September 29, 2023, the U.S. Securities and Exchange Commission (SEC) declared effective a registration statement for Pershing Square SPARC Holdings, Ltd., which is contemplating a unique variation on the traditional special purpose acquisition company (SPAC) structure. This variation, called a SPARC—or special purpose acquisition rights company—was spearheaded by billionaire investor Bill Ackman through his investment fund, Pershing Square Capital Management, L.P., and was designed to address several pain points for SPACs, which have lost popularity after frenzied activities in 2020 and 2021.
Client Highlights
3.06.23
Wilson Sonsini Advises Alteryx on Upsizing, Pricing of $450 Million Senior Notes
On March 1, 2023, Alteryx, Inc. announced that it has priced its offering of $450 million aggregate principal amount of its 8.75 percent senior notes due 2028 in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended. The aggregate principal amount of the offering was increased by $100 million from the previously announced offering size. The offering is expected to close on March 6, 2023, subject to customary closing conditions. Alteryx intends to use the net proceeds of the offering for general corporate purposes, including potential repurchases or repayments of its outstanding convertible notes. The notes will be guaranteed on a senior unsecured basis by certain subsidiaries of the Alteryx. Alteryx UK Ltd will initially guarantee the notes.
Client Highlights
10.19.22
Wilson Sonsini Advises Zymeworks on Exclusive Licensing Agreement with Jazz Pharmaceuticals
On October 19 2022, Zymeworks BC Inc. and Jazz Pharmaceuticals Ireland Ltd. announced that they entered into an exclusive license agreement to develop and commercialize zanidatamab. Under that arrangement, Jazz will receive an exclusive license from Zymeworks to develop and commercialize zanidatamab in the United States, Europe, Japan, and all other territories except for those Asia/Pacific territories that Zymeworks previously licensed to BeiGene, Ltd.
Client Highlights
3.05.21
Wilson Sonsini Advises NightDragon Acquisition Corp. on Initial Public Offering
On March 4, 2021, NightDragon Acquisition Corp. announced the closing of its initial public offering of 34,500,000 SCALE (Stakeholder-Centered Aligned Listed Equity) units, including 4,500,000 SCALE units pursuant to the full exercise of the underwriters’ over-allotment option. Each SCALE unit consists of one share of the company’s Class A common stock and one-fifth of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. The SCALE units were sold at an offering price of $10.00 per SCALE unit, generating gross proceeds of $345,000,000. The SCALE units began trading on Nasdaq on March 2, 2021, under the symbol “NDACU,” and when the securities comprising the SCALE units begin separate trading, the Class A common stock and warrants are expected to be listed on Nasdaq under the symbols “NDAC” and “NDACW,” respectively. Wilson Sonsini Goodrich & Rosati advised NightDragon Acquisition Corp. on the initial public offering.
NightDragon Acquisition Corp. was formed for the purpose of effecting a merger, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. While it may pursue an acquisition opportunity in any business, industry, sector, or geographical location, the company intends to focus its search on the cybersecurity, safety, security, and privacy sector.
Morgan Stanley & Co. LLC acted as lead book-running manager and Drexel Hamilton acted as co-manager in the offering.
The Wilson Sonsini team that advised NightDragon Acquisition Corp. included the following:
Corporate
Jeff Saper
Robert Day
Bryan King
James Babikian
Jeff Buckelew
NightDragon Acquisition Corp. was formed for the purpose of effecting a merger, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. While it may pursue an acquisition opportunity in any business, industry, sector, or geographical location, the company intends to focus its search on the cybersecurity, safety, security, and privacy sector.
Morgan Stanley & Co. LLC acted as lead book-running manager and Drexel Hamilton acted as co-manager in the offering.
The Wilson Sonsini team that advised NightDragon Acquisition Corp. included the following:
Corporate
Jeff Saper
Robert Day
Bryan King
James Babikian
Jeff Buckelew
Client Highlights
9.22.20
Wilson Sonsini Represents Athira Pharma, Inc. in its Initial Public Offering
On September 17, 2020, Athira Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, priced its initial public offering of 12 million shares of its common stock at $17.00 per share. All shares were offered by Athira. The gross proceeds are expected to be $204 million, before deducting underwriting discounts and commissions and estimated offering expenses. Wilson Sonsini represented Athira in connection with the offering.
Client Highlights
1.02.20
NanoString Announces $50 Million Deal with Veracyte
On December 3, 2019, NanoString Technologies, a leading provider of life science tools for translational research, announced a strategic transaction to exclusively license select nCounter-based diagnostic assets and rights to Veracyte for $50 million in cash and Veracyte stock, plus up to $10 million in cash upon satisfaction of future potential milestones. The transaction closed on December 3, 2019. Wilson Sonsini Goodrich & Rosati represented NanoString in the transaction.
Client Highlights
11.11.18
Apptio to Be Acquired by Vista Equity Partners for $1.94 Billion
On November 11, 2018, Apptio, a Washington-based company that develops technology business management software, announced that it has entered an agreement to be acquired by Vista Equity Partners, a tech-focused private equity firm, for a total value of approximately $1.94 billion. Apptio shareholders will receive $38.00 in cash per share, representing a 53 percent premium to the unaffected closing price as of November 9, 2018. Wilson Sonsini Goodrich & Rosati is representing Apptio in the transaction.